Clinical Laserthermia Systems and Focalyx enters co-marketing agreement for image-guided focal laser ablation of prostate cancer
Lund, Sverige – Clinical Laserthermia Systems AB (publ) (“CLS”) today announced that their US subsidiary, CLS Americas, has entered a co-marketing agreement with Focalyx to sell and market an integrated, minimally invasive, fusion-guided focal laser ablation treatment for low-to-intermediate risk prostate cancer patients.CLS’s TRANBERG® Thermal Therapy System and the Focalyx® Fusion image-guidance system will initially be offered to urology clinics under a Mobile Service Provider (MSP) Agreement that includes consumable accessories, training, and on-site clinical